spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Actos  

 HSMN NewsFeed - 16 Feb 2016
Neuralstem Appoints Richard Daly as President and Chief Executive Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 8 Apr 2014
Takeda Responds to Verdict in Diabetes Drug Case
Biopharmaceuticals Endocrinology Litigation
 HSMN NewsFeed - 17 Aug 2012
Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
Biopharmaceuticals Generics Endocrinology
 HSMN NewsFeed - 23 Sep 2010
Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 28 Apr 2010
Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
Biopharmaceuticals Litigation Endocrinology
 HSMN NewsFeed - 24 Feb 2010
GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 13 May 2009
FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 31 Mar 2008
New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 19 Sep 2007
ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 11 Sep 2007
Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 11 Sep 2007
Takeda Statement on ACTOS(R) (pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 11 Sep 2007
GlaxoSmithKline Responds to JAMA Articles
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 6 Jun 2007
Takeda Revises ACTOS(R) (pioglitazone HCl) Prescribing Label
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 13 Nov 2006
New Data Show ACTOS(R) (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2006
ACTOS(R) (pioglitazone HCl) Demonstrates Significant Improvements in Cardiovascular Outcomes for High-Risk Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 21 Jul 2006
Takeda Announces Start of Phase 3 Clinical Program in the U.S. of Fixed Dose Combination Product of Actos(R) + TAK-536 for Treatment of Patients with Type 2 Diabetes Associated with Hypertension
Biopharmaceuticals Endocrinology Cardiology
Return to NewsFeed  

 Additional items found! 25

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 25 additional stories matching:
Actos
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.